[ad_1]
- Virtual English Session:
Tuesday, November 15 at 8:30am – 12:00 PM Eastern Time
November 15 at 9:30pm – November 16 at 1:00 AM Beijing Time
- Hybrid Mandarin Session in Shanghai:
Thursday, November 17 at 1:30pm – 5:30pm Beijing Time
SHANGHAI and HONG KONG, Oct. 26, 2022 /PRNewswire/ — Antengene Corporation Limited (“Antengene” SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for hematology and oncology, today announced that it will host its R&D Day for the investment community on November 15th (Virtual English Session) and November 17th (Hybrid Mandarin Session in Shanghai) since its inception to review Antengene’s R&D strategy and pipeline, the commercial launch of XPOVIO® (selinexor) underway in China and other markets in Asiaand other important company updates.
“We look forward to updating the investment community during Antengene’s R&D Day 2022,” said Dr. Jay MeiAntengene’s Founder, Chairman and CEO. “Over the last year, Antengene has successfully transitioned to an innovative commercial-stage global biopharmaceutical …
Full story available on Benzinga.com
[ad_2]
Source link
